Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

Chervinsky, Paul; Casale, Thomas B.; Townley, Robert G.; Tripathy, Ita; Hedgecock, S.; FowlerTaylor, Angel; Shen, Henry; Fox, Howard

doi:10.1016/s1081-1206(10)62171-0

Cited by 191 publications

(103 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a large pivotal trial, omalizumab decreased serum-free IgE levels and provided clinical benefit in a dose-dependent fashion in patients with seasonal allergic rhinitis (768,1733). In adults and adolescents, omalizumab was found to decrease all nasal symptoms and to improve RQLQ in patients with rhinitis induced by birch and ragweed pollens as well as in those with sensitization to outdoor allergens (1105,1734). In patients with asthma and rhinitis, omalizumab improved nasal and bronchial symptoms and reduced unscheduled visits due to asthma (770).…”

Section: Anti-igementioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,812

1,761

View full text Add to dashboard Cite

Section: Anti-igementioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,812

1,761

View full text Add to dashboard Cite

“…Among these, omalizumab, a humanized monoclonal antibody that binds circulating IgE and prevents its attachment to high-affinity IgE receptors, is the most extensively studied agent approved for the treatment of severe uncontrolled asthma with perennial sensitizations. However, a growing number of reports indicate its effectiveness in seasonal and perennial AR in adults/adolescents [90][91][92][93][94] and children [95][96][97][98][99]. Targeting the early phase of the allergic cascade could prove a significant allergic march-preventing treatment.…”

Section: Other Interventionsmentioning

confidence: 99%

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

et al. 2013

View full text Add to dashboard Cite

The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of 'united airways disease' or 'respiratory allergy', implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the 'atopic march'. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.

show abstract

“…Posthoc analyses of subgroups that had been previously unresponsive to allergen immunotherapy or intranasal steroids demonstrated that these patients showed considerable improvement. 11 …”

Section: Perennial Allergic Rhinitismentioning

confidence: 99%

Untitled

2018

MOJI

View full text Add to dashboard Cite

Here, recent literature on the use of omalizumab in sino-nasal allergic diseases is reviewed. Omalizumab is an anti-human IgE humanized monoclonal antibody produced against CƐ3 domain of the Fc fragment of IgE molecule. Omalizumab suppresses the effector functions of IgE by preventing binding to high-affinity receptors (FcεR1) on allergy related immune effector cells, blocking mast cell or basophil mediator release. Omalizumab is helpful mainly in ragweed/birch pollen-induced seasonal and perennial allergic rhinitis rather than uncontrolled and concomitant allergic rhinitis and asthma/chronic rhino-sinusitis/nasal polyposis.

show abstract

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

Cited by 191 publications

References 18 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

Untitled

Contact Info

Product

Resources

About